CN114949338A - 一种可持久抗耐药菌水凝胶及其制备方法和应用 - Google Patents
一种可持久抗耐药菌水凝胶及其制备方法和应用 Download PDFInfo
- Publication number
- CN114949338A CN114949338A CN202210592222.1A CN202210592222A CN114949338A CN 114949338 A CN114949338 A CN 114949338A CN 202210592222 A CN202210592222 A CN 202210592222A CN 114949338 A CN114949338 A CN 114949338A
- Authority
- CN
- China
- Prior art keywords
- hydrogel
- solution
- preparing
- drug
- antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 121
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title claims abstract description 25
- 241000894006 Bacteria Species 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 60
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 37
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 37
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims abstract description 30
- 235000012907 honey Nutrition 0.000 claims abstract description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 14
- 239000001257 hydrogen Substances 0.000 claims abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 5
- 239000008103 glucose Substances 0.000 claims abstract description 5
- 229930091371 Fructose Natural products 0.000 claims abstract description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 4
- 239000005715 Fructose Substances 0.000 claims abstract description 4
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 54
- 239000011259 mixed solution Substances 0.000 claims description 25
- 230000008014 freezing Effects 0.000 claims description 22
- 238000007710 freezing Methods 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000002861 polymer material Substances 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 12
- 229920001059 synthetic polymer Polymers 0.000 claims description 10
- 238000010257 thawing Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 206010072170 Skin wound Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 abstract description 21
- 235000002949 phytic acid Nutrition 0.000 abstract description 21
- 229940068041 phytic acid Drugs 0.000 abstract description 21
- 239000000467 phytic acid Substances 0.000 abstract description 21
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 19
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 7
- 238000004132 cross linking Methods 0.000 abstract description 5
- 238000001179 sorption measurement Methods 0.000 abstract description 5
- 238000010382 chemical cross-linking Methods 0.000 abstract description 2
- 231100000481 chemical toxicant Toxicity 0.000 abstract description 2
- 239000003431 cross linking reagent Substances 0.000 abstract description 2
- 239000003440 toxic substance Substances 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000003999 initiator Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 description 12
- 238000001723 curing Methods 0.000 description 11
- 230000003385 bacteriostatic effect Effects 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 238000001792 White test Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- -1 silver ions Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Insects & Arthropods (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明公开了一种可持久抗耐药菌水凝胶及其制备方法和应用。本发明主要以聚乙烯醇为基材,通过添加植酸和蜂蜜中的葡萄糖和果糖对其进行改性而成。抗菌水凝胶的制备过程中未添加有毒性的化学交联剂或者引发剂,主要通过聚乙烯醇、植酸和单糖之间的酯键、氢键和静电吸附作用交联而成。同时,在聚乙烯醇基材中加入植酸和蜂蜜后,水凝胶对金葡萄球菌、耐药性金葡萄球菌和铜绿假单胞菌都有比较显著持久的抗菌效果,抗菌时间能维持3个月左右。同时,有机水凝胶还具有很好的可拉伸性和和较高的导电性,为其在基于生物敷料的柔性电子器件上的应用提供了有利的条件。
Description
技术领域
本发明属于生物敷料领域的一种抗菌水凝胶的制备方法,具体涉及了一种可持久抗耐药菌水凝胶及其制备方法和应用。
背景技术
伤口敷料已成为生物医学材料研究的一个重要分支。伤口细菌感染严重的情况下会引发其他疾病甚至影响生命。在新冠肺炎病毒流行的当下,细菌传染病和细菌感染的环境一直威胁着世界各地人类的健康。自首次发现青霉素以来,抗生素已经提供了一种有效的治疗细菌感染性疾病的方法。但是,由于抗生素的过度使用或使用不当导致细菌耐药性的增加,导致情况更加恶化。因此,越来越多的抗菌生物材料在某些情况下被开发作为抗生素的替代品。其中,抗菌水凝胶由于制备过程简单,结构多样性和可以负载抗菌剂等优点吸引了广泛的关注。
水凝胶是一类通过化学或者物理交联形成的三维网络凝胶。由于其优越的生物相容性、可控的物理性质、天然的载药结构和丰富的功能基团,水凝胶逐渐成为医学创面研究的热点。迄今为止,水凝胶已成功应用于治疗皮肤缺损、感染创面、烧伤创面、糖尿病足和体内湿性创面等。根据感染创面情况的不同,水凝胶需要具备良好的组织黏附性、优异的机械性能、持久的抗菌能力。由于水凝胶有着和皮肤相似的杨氏模量(0.5-1.95MPa)、柔韧性、含水量(>70%)以及透气性等物化性质,可以给创面提供一个抗菌的湿润环境。目前,水凝胶抗菌的方式主要有两种,一种是通过负载抗菌剂,比如壳聚糖、金属纳米粒子(Ag、Cu、Zn)来破坏细菌的细胞壁,另一种是通过水凝胶自身的物理化学结构和细菌的相互作用来达到抗菌作用。前一种方式已经发展的较为成熟,并且有许多研究证实了银离子的出色的抗菌效果。然而基于材料本身结构的抗菌机理和抗菌效果还不够完善。
发明内容
为了解决背景技术中存在的问题和需求,本发明提出了一种通过植酸和蜂蜜改性的聚乙烯醇基抗菌水凝胶及其制备方法和应用,其中,蜂蜜和植酸是两种天然高分子材料,这两种材料都具有较好的亲水性和生物兼容性。文献“The antibacterial activities ofhoney”(Saad Almasaudi,Saudi Journal of Biological Sciences,2188-2196,2021)中提到蜂蜜的pH值一般在3.2-4.5左右,大部分的微生物和细菌主要生活在pH值为6.5-7.5的中性环境中,这样的低酸碱度还能促进组织修复。蜂蜜中的糖含量,多酚化合物和过氧化氢等多种物质都有助于蜂蜜的抗菌功效。植酸,又称作肌醇六磷酸,由于它有很丰富的磷酸基团,能够在加热条件下和聚乙烯醇、葡萄糖等糖类发生酯化反应,从而得到一种酯键、氢键、静电吸附作用交联的紧密网络结构。通过利用蜂蜜和植酸对聚乙烯醇进行改性后,该水凝胶能够对金葡萄球菌、耐药性金葡萄球菌和铜绿假单胞菌有很好的抗菌效果,因此抗菌水凝胶也为有机水凝胶,适用于但不限于生物医用敷料领域。
本发明的技术方案如下:
一、一种可持久抗耐药菌水凝胶的制备方法
方法包括以下步骤:
1)配置含氢键的合成或半合成高分子材料溶液:将含氢键的合成或半合成高分子材料溶于去离子水中,进行加热搅拌,得到含氢键的合成或半合成高分子材料溶液;
2)配置混合溶液:将含氢键的合成或半合成高分子材料溶液与植酸溶液、蜂蜜以质量比5:5:2的比例进行搅拌混合,搅拌至溶液均匀无杂质为止,再静置去除气泡后,得到透明的混合溶液;
3)对混合溶液进行预固化处理:在80℃水浴加热的条件下对混合溶液进行预固化,预固化后的溶液呈棕色粘稠状且表面有一层薄膜,揭开薄膜后,得到预固化的水凝胶溶液;
4)制备抗菌水凝胶:将预固化好的水凝胶溶液倒入准备好的模具中,然后进行多次冷冻解冻循环,得到固化好的水凝胶。
方法还包括以下步骤:
5)将固化好的水凝胶脱模:待固化好的水凝胶固化完全后,将固化完全的水凝胶从模具中揭开,放至冰箱冷冻中保存。
所述步骤1)中,聚乙烯醇溶液的固含量为10-20%,溶解温度为60℃,搅拌时间为24h,搅拌速度为800rpm/min。
所述步骤2)中,植酸溶液的质量百分浓度为1~5%。
所述步骤2)中,蜂蜜为含单糖含量较高的蜂蜜,具体地,蜂蜜中的葡萄糖和果糖含量均大于20%。
所述步骤4)中,冷冻解冻循环的冷冻温度为-48℃,冷冻时间为2h;解冻温度为室温,解冻时间为30min,冷冻解冻循环的次数为3次。
所述步骤1)中含氢键的合成或半合成高分子材料为下列高分子材料一种或多种:聚乙烯醇、聚乙二醇、纤维素衍生物,其中纤维素衍生物具体为羧甲基纤维素、羟丙基纤维素,所述水凝胶中合成或半合成高分子的重量百分浓度为10%~20%。
二、一种可持久抗耐药菌水凝胶。
三、所述的一种可持久抗耐药菌水凝胶在制备皮肤伤口敷料中的应用。
本发明中的水凝胶是一种不需添加任何有毒化学交联剂的抗菌水凝胶,主要是通过以聚乙烯醇为基材,通过复合植酸和蜂蜜对其改性制得。传统的聚乙烯醇水凝胶基本不具备抗菌性能,并且制备得到的水凝胶结构比较单一,力学性能比较差。而利用植酸和蜂蜜对聚乙烯醇进行改性后,该水凝胶中由于存在酯键、氢键和静电吸附作用等共价键和非共价键作用,力学性能有了很大的改善。同时,蜂蜜中自带的一些抗菌成分也具有一定的抗菌效果。
该水凝胶抗菌的主要机理可以分为几个方面:
(1)蜂蜜的pH值较低,不利于细菌生存。
(2)蜂蜜中的葡萄糖、果糖浓度较高,这些糖类所带的正电荷会与细菌表面的负电荷发生静电吸附作用,从而破坏细胞壁,杀死细菌。
(3)植酸的六个磷酸基团会螯合蜂蜜中的金属离子(K+为主),从而破坏细菌的细胞壁。
(4)在水凝胶制备过程中进行加热,会促进蜂蜜中的过氧化氢成分的增加,过氧化氢具有杀菌作用且能刺激血管内皮生长因子的产生。
本发明的有益效果为:
本发明的抗菌水凝胶对金葡萄球菌、耐药性金葡萄球菌和铜绿假单胞菌的具有显著的体外和小白鼠体内抗菌效果,同时,对耐药性的金葡萄球菌也能在三个月内维持较好的体外抗菌效果。
附图说明
图1为基于聚乙烯醇、植酸和蜂蜜的抗菌水凝胶的结构示意图;
图2为在37℃恒温下放置24h后,抗菌水凝胶对金葡萄球菌、耐药性金葡萄球菌和铜绿假单胞菌的体外抗菌效果;
图3为在37℃恒温下放置三个月后抗菌水凝胶对金葡萄球菌、耐药性金葡萄球菌和铜绿假单胞菌的体外抗菌效果。
具体实施方式
下面结合附图及具体实施例对本发明作进一步详细说明:
实施例1
1)配置固含量为10%的聚乙烯醇溶液:将1g聚乙烯醇加入9g去离子水中,60℃下搅拌溶解24h,搅拌速度为800rpm/min,得到透明粘稠的聚乙烯醇溶液并保存备用;
2)制备混合溶液:将5g质量百分浓度为1%的植酸溶液和2g蜂蜜分别加入到5g固含量为10%的聚乙烯醇溶液中,在70℃的加热条件下搅拌混合均匀至无杂质为止,搅拌速度为700rpm/min,静置半小时除泡后,得到透明的混合溶液;这边不使用真空除气泡的方法,因为溶液粘稠会导致大量气泡聚集在表面,更难消泡。
3)对混合溶液进行预固化处理:在80℃水浴加热的条件下对混合溶液进行预固化,持续2小时,预固化后的溶液呈浅棕色粘稠状且表面有一层薄膜,是表层溶液在加热过程中快速失水形成,用镊子揭开薄膜后,得到预固化的水凝胶溶液;
4)制备抗菌水凝胶:将预固化好的水凝胶溶液倒入准备好的模具中,然后进行3次冷冻解冻循环,得到固化好的水凝胶,固化好的水凝胶具有弹性。
5)将固化好的水凝胶脱模:待固化好的水凝胶固化完全后,将固化完全的水凝胶从模具中揭开,放至冰箱冷冻中保存。
实施例2
1)配置固含量为15%的聚乙烯醇溶液:将1.5g聚乙烯醇加入8.5g去离子水中,60℃下搅拌溶解24h,得到透明粘稠的聚乙烯醇溶液并保存备用;
2)制备混合溶液:将5g质量百分浓度为1%的植酸溶液和2g蜂蜜溶液分别加入到5g固含量为15%的聚乙烯醇溶液中,在70℃的加热条件下搅拌混合均匀,搅拌速度为700rpm/min,静置半小时除泡后,得到透明的混合溶液;
3)对混合溶液进行预固化处理:在80℃水浴加热的条件下对混合溶液进行预固化,持续2小时左右,预固化后的溶液呈浅棕色粘稠状且表面有一层薄膜,用镊子揭开薄膜后,得到预固化的水凝胶溶液;
4)制备抗菌水凝胶:将预固化好的水凝胶溶液倒入准备好的模具中,然后进行3次冷冻解冻循环,得到固化好的水凝胶,固化好的水凝胶具有弹性。
5)将固化好的水凝胶脱模:待固化好的水凝胶固化完全后,将固化完全的水凝胶从模具中揭开,放至冰箱冷冻中保存。
实施例3
1)配置固含量为20%的聚乙烯醇溶液:将2g聚乙烯醇加入8g去离子水中,60℃下搅拌溶解24h,保存备用;
2)制备混合溶液:将5g质量百分浓度为1%的植酸溶液和2g蜂蜜溶液分别加入到5g固含量为20%的聚乙烯醇溶液中,在70℃的加热条件下搅拌混合均匀,静置除泡后,得到透明的混合溶液;
3)对混合溶液进行预固化处理:将上述混合除泡后的混合物溶液在80℃水浴加热的条件下进行预固化,预固化后的液体呈浅棕色粘稠状,溶液表面有一层薄膜,用镊子揭开薄膜后,得到预固化的水凝胶溶液;
4)制备抗菌水凝胶:将预固化好的水凝胶粘稠溶液倒入准备好的模具中,然后进行冷冻解冻固化,可得到具有弹性的抗菌水凝胶。
5)将固化好的水凝胶脱模:待固化好的水凝胶固化完全后,将固化完全的水凝胶从模具中揭开,放至冰箱冷冻中保存。
实施例1-3中分别改变了抗菌水凝胶中的聚乙烯醇溶液的质量浓度,由于聚乙烯醇在水凝胶中的主要功能是作为支架,所以改变聚乙烯醇的质量浓度,可以调节水凝胶的力学性能,具体可描述为:当聚乙烯醇的浓度从10%增加至20%时,该抗菌水凝胶的力学强度杨氏模量会随之增加。由于抗菌水凝胶的使用对象是人体皮肤,弹性较好力学强度弱的水凝胶会提高使用的舒适度,但是并不会影响水凝胶的抗菌性能,所以优选聚乙烯醇质量百分浓度为10%。
实施例1-3中的抗菌水凝胶结构如附图1所示,水凝胶的交联结构中含共价键酯键)和非共价键氢键和静电吸附作用)。对金葡萄球菌、耐药性金葡萄球菌和铜绿假单胞菌的体外抗菌效果如附图2所示,可以观察到抗菌凝胶的抑菌直径远远大于抗生素的抑菌直径,图中的blank为空白组,Anti为抗生素组。附图3为图2中的水凝胶放置3个月后的抑菌效果,可以观察到,三个月后,细菌已经对抗生素产生耐药性,但是抗菌水凝胶的抑菌效果依旧良好,说明了本发明中抗菌水凝胶的抗菌、抑菌的持久性。
实施例1中实验组(植酸质量百分浓度为1%)、空白对照组和抗体组的体外抗菌的抑菌直径数据如下表所示,对照组和抗体组的白色试验纸尺寸为6mm。
表1:实验组(植酸质量百分浓度为1%)、空白对照组和抗体组的体外抗菌的抑菌直径数据表
细菌种类 | 实验组(1%) | 对照组 | 抗体组 |
金葡萄球菌 | 10.74mm | <6mm | 8.4 |
耐药性金葡萄球菌 | 9.5mm | <6mm | <6mm |
铜绿假单胞菌 | 10.6mm | <6mm | 10.3mm |
实施例4
1)配置固含量为10%的聚乙烯醇溶液:将1g聚乙烯醇加入9g去离子水中,60℃下搅拌溶解24h,保存备用;
2)制备混合溶液:将5g质量百分浓度为2.5%的植酸溶液和2g蜂蜜溶液分别加入到5g固含量为10%的聚乙烯醇溶液中,在70℃的加热条件下搅拌混合均匀,静置除泡后,得到透明的混合溶液;
3)对混合溶液进行预固化处理:将上述混合除泡后的混合物溶液在80℃水浴加热的条件下进行预固化,预固化后的液体呈浅棕色粘稠状,溶液表面有一层薄膜,用镊子揭开薄膜后,得到预固化的水凝胶溶液;
4)制备抗菌水凝胶:将预固化好的水凝胶粘稠溶液倒入准备好的模具中,然后进行冷冻解冻固化,可得到具有弹性的抗菌水凝胶。
5)将固化好的水凝胶脱模:待固化好的水凝胶固化完全后,将固化完全的水凝胶从模具中揭开,放至冰箱冷冻中保存。
实施例4中实验组(植酸质量百分浓度为2.5%)、空白对照组和抗体组的体外抗菌的抑菌直径数据如下表所示,对照组和抗体组的白色试验纸尺寸为6mm。
表2:实验组(植酸质量百分浓度为2.5%)、空白对照组和抗体组的体外抗菌的抑菌直径数据表
细菌种类 | 实验组(2.5%) | 对照组 | 抗体组 |
金葡萄球菌 | 12.9mm | <6mm | 8.4 |
耐药性金葡萄球菌 | 10.7mm | <6mm | <6mm |
铜绿假单胞菌 | 11.5mm | <6mm | 10.3mm |
实施例5
1)配置固含量为10%的聚乙烯醇溶液:将1g聚乙烯醇加入9g去离子水中,60℃下搅拌溶解24h,保存备用;
2)制备混合溶液:将5g质量百分浓度为5%的植酸溶液和2g蜂蜜溶液分别加入到5g固含量为10%的聚乙烯醇溶液中,在70℃的加热条件下搅拌混合均匀,静置除泡后,得到透明的混合溶液;
3)对混合溶液进行预固化处理:将上述混合除泡后的混合物溶液在80℃水浴加热的条件下进行预固化,预固化后的液体呈浅棕色粘稠状,溶液表面有一层薄膜,用镊子揭开薄膜后,得到预固化的水凝胶溶液;
4)制备抗菌水凝胶:将预固化好的水凝胶粘稠溶液倒入准备好的模具中,然后进行冷冻解冻固化,可得到具有弹性的抗菌水凝胶。
5)将固化好的水凝胶脱模:待固化好的水凝胶固化完全后,将固化完全的水凝胶从模具中揭开,放至冰箱冷冻中保存。
实施例5中实验组(植酸质量百分浓度为5%)、空白对照组和抗体组的体外抗菌的抑菌直径数据如下表所示,对照组和抗体组的白色试验纸尺寸为6mm。
表3:实验组(植酸质量百分浓度为5%)、空白对照组和抗体组的体外抗菌的抑菌直径数据表
细菌种类 | 实验组(5%) | 对照组 | 抗体组 |
金葡萄球菌 | 15mm | <6mm | 8.4 |
耐药性金葡萄球菌 | 11.5mm | <6mm | <6mm |
铜绿假单胞菌 | 14.5mm | <6mm | 10.3mm |
实施例1,4-5中改变了水凝胶中的植酸含量,从质量百分浓度1%增加至5%,从表1-3中的体外抗菌数据可以看出增加植酸的含量,可以提高抗菌水凝胶的抑菌直径,这是由于增加了植酸的质量浓度,增加了酯键的含量,提高了水凝胶的交联密度,从而破坏细菌的细胞壁,有效的抑制了细菌的活性。
Claims (9)
1.一种可持久抗耐药菌水凝胶的制备方法,其特征在于,包括以下步骤:
1)配置含氢键的合成或半合成高分子材料溶液:将含氢键的合成或半合成高分子材料溶于去离子水中,进行加热搅拌,得到含氢键的合成或半合成高分子材料溶液;
2)配置混合溶液:将含氢键的合成或半合成高分子材料溶液与植酸溶液、蜂蜜以质量比5:5:2的比例进行搅拌混合,搅拌至溶液均匀无杂质为止,再静置去除气泡后,得到透明的混合溶液;
3)对混合溶液进行预固化处理:在80℃水浴加热的条件下对混合溶液进行预固化,预固化后的溶液呈棕色粘稠状且表面有一层薄膜,揭开薄膜后,得到预固化的水凝胶溶液;
4)制备抗菌水凝胶:将预固化好的水凝胶溶液倒入准备好的模具中,然后进行多次冷冻解冻循环,得到固化好的水凝胶。
2.根据权利要求1所述的一种可持久抗耐药菌水凝胶的制备方法,其特征在于,方法还包括以下步骤:
5)将固化好的水凝胶脱模:待固化好的水凝胶固化完全后,将固化完全的水凝胶从模具中揭开,放至冰箱冷冻中保存。
3.根据权利要求1所述的一种可持久抗耐药菌水凝胶的制备方法,其特征在于,所述步骤1)中,聚乙烯醇溶液的固含量为10-20%,溶解温度为60℃,搅拌时间为24h,搅拌速度为800rpm/min。
4.根据权利要求1所述的一种可持久抗耐药菌水凝胶的制备方法,其特征在于,所述步骤2)中,植酸溶液的质量百分浓度为1~5%。
5.根据权利要求1所述的一种可持久抗耐药菌水凝胶的制备方法,其特征在于,所述步骤2)中,蜂蜜为含单糖含量较高的蜂蜜,具体地,蜂蜜中的葡萄糖和果糖含量均大于20%。
6.根据权利要求1所述的一种可持久抗耐药菌水凝胶的制备方法,其特征在于,所述步骤4)中,冷冻解冻循环的冷冻温度为-48℃,冷冻时间为2h;解冻温度为室温,解冻时间为30min,冷冻解冻循环的次数为3次。
7.根据权利要求1所述的一种可持久抗耐药菌水凝胶的制备方法,其特征在于,所述步骤1)中含氢键的合成或半合成高分子材料为下列高分子材料一种或多种:聚乙烯醇、聚乙二醇、纤维素衍生物。
8.一种可持久抗耐药菌水凝胶,其特征在于,所述可持久抗耐药菌水凝胶是根据权利要求1-7任一所述的制备方法制得的。
9.根据权利要求8所述的一种可持久抗耐药菌水凝胶在制备皮肤伤口敷料中的应用。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210592222.1A CN114949338B (zh) | 2022-05-27 | 2022-05-27 | 一种可持久抗耐药菌水凝胶及其制备方法和应用 |
US18/132,978 US20230381325A1 (en) | 2022-05-27 | 2023-04-11 | Long-lasting hydrogel for use against drug-resistant bacteria and preparation method and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210592222.1A CN114949338B (zh) | 2022-05-27 | 2022-05-27 | 一种可持久抗耐药菌水凝胶及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114949338A true CN114949338A (zh) | 2022-08-30 |
CN114949338B CN114949338B (zh) | 2023-01-10 |
Family
ID=82958014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210592222.1A Active CN114949338B (zh) | 2022-05-27 | 2022-05-27 | 一种可持久抗耐药菌水凝胶及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20230381325A1 (zh) |
CN (1) | CN114949338B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107987439A (zh) * | 2017-12-19 | 2018-05-04 | 武汉理工大学 | 一种聚乙烯醇基抗菌水凝胶及其制备方法和应用 |
CN108283727A (zh) * | 2018-03-26 | 2018-07-17 | 广东工业大学 | 一种纳米纤维敷料及其制备方法 |
CN110467735A (zh) * | 2019-06-20 | 2019-11-19 | 哈尔滨工程大学 | 一种水凝胶及其制备方法和含水凝胶的制品 |
CN110694102A (zh) * | 2019-11-13 | 2020-01-17 | 中国矿业大学 | 一种具有长效抗菌作用的3d打印水凝胶伤口敷料 |
CN110755678A (zh) * | 2019-11-13 | 2020-02-07 | 中国矿业大学 | 一种基于绿色原位还原的3d打印抗菌水凝胶伤口敷料 |
WO2021100045A1 (en) * | 2019-11-19 | 2021-05-27 | Sion Biotext Medical Ltd. | Wound dressing comprising a combination of hydrogel and honey, method of preparation and uses thereof |
CN113637183A (zh) * | 2021-08-17 | 2021-11-12 | 安徽大学 | 改性石墨烯负载纳米银/聚乙烯醇抗菌水凝胶及其制备方法 |
-
2022
- 2022-05-27 CN CN202210592222.1A patent/CN114949338B/zh active Active
-
2023
- 2023-04-11 US US18/132,978 patent/US20230381325A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107987439A (zh) * | 2017-12-19 | 2018-05-04 | 武汉理工大学 | 一种聚乙烯醇基抗菌水凝胶及其制备方法和应用 |
CN108283727A (zh) * | 2018-03-26 | 2018-07-17 | 广东工业大学 | 一种纳米纤维敷料及其制备方法 |
CN110467735A (zh) * | 2019-06-20 | 2019-11-19 | 哈尔滨工程大学 | 一种水凝胶及其制备方法和含水凝胶的制品 |
CN110694102A (zh) * | 2019-11-13 | 2020-01-17 | 中国矿业大学 | 一种具有长效抗菌作用的3d打印水凝胶伤口敷料 |
CN110755678A (zh) * | 2019-11-13 | 2020-02-07 | 中国矿业大学 | 一种基于绿色原位还原的3d打印抗菌水凝胶伤口敷料 |
WO2021100045A1 (en) * | 2019-11-19 | 2021-05-27 | Sion Biotext Medical Ltd. | Wound dressing comprising a combination of hydrogel and honey, method of preparation and uses thereof |
CN113637183A (zh) * | 2021-08-17 | 2021-11-12 | 安徽大学 | 改性石墨烯负载纳米银/聚乙烯醇抗菌水凝胶及其制备方法 |
Non-Patent Citations (1)
Title |
---|
司徒方民等: "聚乙烯醇/季铵盐壳聚糖复合水凝胶的制备及其烫伤敷料的应用", 《功能材料》 * |
Also Published As
Publication number | Publication date |
---|---|
CN114949338B (zh) | 2023-01-10 |
US20230381325A1 (en) | 2023-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Khan et al. | Novel functional antimicrobial and biocompatible arabinoxylan/guar gum hydrogel for skin wound dressing applications | |
CN110354295B (zh) | 一种光热转换材料及其制备方法 | |
WO2019091150A1 (zh) | 一种藻酸盐创面修复敷料及其制备方法 | |
Naghshineh et al. | Preparation of chitosan, sodium alginate, gelatin and collagen biodegradable sponge composites and their application in wound healing and curcumin delivery | |
TWI401098B (zh) | 傷口敷料 | |
Joshi Navare et al. | Needle-injectable microcomposite cryogel scaffolds with antimicrobial properties | |
Hiranpattanakul et al. | Fabrication of a chitin/chitosan hydrocolloid wound dressing and evaluation of its bioactive properties | |
CN110507842B (zh) | 一种细菌纤维素/透明质酸/ε-聚赖氨酸功能型敷料及其制备方法 | |
CN106110383A (zh) | 一种壳聚糖藻酸盐敷料及其冻干制备方法 | |
CN115124738B (zh) | 一种双层仿生载药水凝胶及其制备与应用 | |
CN115154642A (zh) | 一种仿生非对称海绵敷料及其制备方法 | |
CN110152055A (zh) | 海藻酸胺化衍生物/细菌纤维素纳米晶复合凝胶构筑的功能性药物缓释医用敷料 | |
CN106947095A (zh) | 一种用于伤口愈合抑菌型水凝胶的制备方法 | |
Rasouli et al. | Bacterial cellulose as potential dressing and scaffold material: toward improving the antibacterial and cell adhesion properties | |
CN106344954A (zh) | 一种生物抗菌细菌纤维素敷料及其制备方法 | |
Xiao et al. | A novel conductive antibacterial nanocomposite hydrogel dressing for healing of severely infected wounds | |
CN111073001A (zh) | 一种两性葡聚糖水凝胶及应用 | |
Hassabo et al. | Natural polymers in medical textiles | |
CN114949338B (zh) | 一种可持久抗耐药菌水凝胶及其制备方法和应用 | |
CN115850733B (zh) | 一种可注射用纳米粘土水凝胶及其制备方法和应用 | |
CN112691231A (zh) | 一种聚乙烯醇/海藻酸钠/季铵化聚己缩胍抑菌凝胶及其制备方法 | |
CN113045848B (zh) | 一种聚乙烯醇纳米复合水凝胶的制备方法 | |
US20200306289A1 (en) | Wound healing topical formulation and preparation thereof | |
CN109381734A (zh) | 一种厚度和粗糙度可控的海藻酸钙膜抗菌敷料的制备方法 | |
Pasaribu et al. | A review: Current trends and future perspectives of bacterial nanocellulose-based wound dressings |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |